{"id":815875,"date":"2025-02-20T16:15:52","date_gmt":"2025-02-20T21:15:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/"},"modified":"2025-02-20T16:15:52","modified_gmt":"2025-02-20T21:15:52","slug":"y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/","title":{"rendered":"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Feb.  20, 2025  (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025.<\/p>\n<p align=\"justify\">Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oLDjcFTwqjECtPB98sNNihKRWk_Go8ENJ-HsEvhmPODc__tkDQ2__gvXxj-yx8W9P_9cNFopGhre9gA93wnCcyMBKVivsLpYhyIkcmOm1ED2-q_HKjl9jKBu9s6s4ZpZPy35DBW9d72Xr1vTZ2hFjA==\" rel=\"nofollow\" target=\"_blank\">here<\/a>. A live audio webcast of the call will be available on the Investor Relations section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AM8VDrTxZUEJyJBU-iAx3KnYBuU194zRhvi1wTW5ttM9gSkn4AfFQVp5a9M6OOeMJG_T6oDDw-3ycAxlRqNB9mvlvDU4KrjE2GpU1pcRt3x9nN0j9-yUWJnvOqVHuJD8VDiQKHcNCw9QVbGZj8baeIeiCHxsL0wYEdVaSXcSC7s=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.ymabs.com\/events-and-presentations\/events<\/a>. The webcast will be archived for at least 30 days.<\/p>\n<p align=\"justify\">\n        <strong>About Y-mAbs <\/strong>\n      <\/p>\n<p align=\"justify\">Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company\u2019s technologies include its investigational Self-Assembly DisAssembly (\u201cSADA\u201d) Pretargeted Radioimmunotherapy Platform (\u201cPRIT\u201d) and bispecific antibodies generated using the Y-BiClone platform. The Company\u2019s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA\u00ae (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond. Words such as \u2018\u2018anticipate,\u2019\u2019 \u2018\u2018believe,\u2019\u2019 \u201ccontemplate,\u201d \u2018\u2018continue,\u2019\u2019 \u2018\u2018could,\u2019\u2019 \u2018\u2018estimate,\u2019\u2019 \u2018\u2018expect,\u2019\u2019 \u201chope,\u201d \u2018\u2018intend,\u2019\u2019 \u2018\u2018may,\u2019\u2019 \u2018\u2018might,\u2019\u2019 \u2018\u2018plan,\u2019\u2019 \u2018\u2018potential,\u2019\u2019 \u2018\u2018predict,\u2019\u2019 \u2018\u2018project,\u2019\u2019 \u2018\u2018should,\u2019\u2019 \u2018\u2018target,\u2019\u2019 \u201cwill,\u201d \u2018\u2018would\u2019,\u2019 \u201cguidance,\u201d \u201cgoal,\u201d \u201cobjective,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company\u2019s business is subject to risks and uncertainties affecting the Company including those described in the \u201cRisk Factors\u201d section included in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\u00a0December 31, 2023, and the Company\u2019s Quarterly Report on Form 10-Q for the quarterly periods ended\u00a0March 31, 2024, and\u00a0September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p align=\"justify\">SADA<sup>\u00ae<\/sup>, SADA PRIT\u2122, DANYELZA<sup>\u00ae<\/sup>\u00a0and Y-mAbs<sup>\u00ae<\/sup>\u00a0are registered trademarks of\u00a0Y-mAbs Therapeutics, Inc.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Courtney Dugan<br \/>VP, Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vvevwwxkXDP_wfFEzDgcwcA1U-7G1rh3dP4IWath_P8qJhTMnjgo7piwED_To6C03XXP42l52JR9wkT0Ku2Qlw==\" rel=\"nofollow\" target=\"_blank\">cdu@ymabs.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDIxMWUyNDYtZjYzZC00NDZmLWIzMmQtYjU5ZGJlZDRlMzFjLTUwMDA1MDgxNw==\/tiny\/Y-mAbs-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of the Company\u2019s website at https:\/\/ir.ymabs.com\/events-and-presentations\/events. The webcast will be archived for at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815875","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of the Company\u2019s website at https:\/\/ir.ymabs.com\/events-and-presentations\/events. The webcast will be archived for at &hellip; Continue reading &quot;Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T21:15:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025\",\"datePublished\":\"2025-02-20T21:15:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/\"},\"wordCount\":458,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/\",\"name\":\"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==\",\"datePublished\":\"2025-02-20T21:15:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/","og_locale":"en_US","og_type":"article","og_title":"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - Market Newsdesk","og_description":"NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of the Company\u2019s website at https:\/\/ir.ymabs.com\/events-and-presentations\/events. The webcast will be archived for at &hellip; Continue reading \"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T21:15:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025","datePublished":"2025-02-20T21:15:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/"},"wordCount":458,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/","name":"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==","datePublished":"2025-02-20T21:15:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA0NiM2NzYxMzIzIzUwMDA1MDgxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-fourth-quarter-and-full-year-2024-financial-and-operating-results-on-march-4-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815875"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815875\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}